Melanoma proliferation and chemoresistance controlled by the DEK oncogene

Cancer Research

Volumn 69, Issue 16, 2009, Pages 6405-6413

  Khodadoust, Michael S ^a   Verhaegen, Monique ^a   Kappes, Ferdinand ^b   Riveiro Falkenbach, Erica ^c   Cigudosa, Juan C ^c   Kim, David S L ^a   Chinnaiyan, Arul M ^a   Markovitz, David M ^a,b   Soengas, María S ^a,c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DEK PROTEIN; DOXORUBICIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN P53; SHORT HAIRPIN RNA; TUMOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CHROMOSOME 6; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; GENE CONTROL; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MAPPING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; ONCOGENE; PHENOTYPE; PREMATURITY; PRIORITY JOURNAL; PROTEIN CONTENT; SENESCENCE; TRANSCRIPTION INITIATION; TUMOR PROMOTION; UPREGULATION;

BCL-X PROTEIN; CELL AGING; CELL PROLIFERATION; CELLS, CULTURED; CHROMOSOMAL PROTEINS, NON-HISTONE; CHROMOSOMES, HUMAN, PAIR 6; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 69249144800     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-1063     Document Type: Article

References (49)

1. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007;445:851-7.
2. Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 2006;20:2149-82.
3. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003;22:3138-51.
4. McGill GG, Horstmann M, Widlund HR, et al. Bcl2 regulation by the melanocyte master regulator mitf modulates lineage survival and melanoma cell viability. Cell 2002;109:707-18.
5. Kutuk O, Letai A. Regulation of Bcl-2 family proteins by posttranslational modifications. Curr Mol Med 2008; 8:102-18.
6. Verhaegen M, Bauer JA, Martin de la Vega C, et al. A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res 2006;66:11348-59.
7. Ueda Y, Richmond A. NF-κB activation in melanoma. Pigment Cell Res 2006;19:112-24.
8. Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer 2007;109:455-64.
9. Santos GC, Zielenska M, Prasad M, Squire JA. Chromosome 6p amplification and cancer progression. J Clin Pathol 2007;60:1-7.
10. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353:2135-47.
11. Namiki T, Yanagawa S, Izumo T, et al. Genomic alterations in primary cutaneous melanomas detected by metaphase comparative genomic hybridization with laser capture or manual microdissection: 6p gains may predict poor outcome. Cancer Genet Cytogenet 2005; 157:1-11.
12. Hoglund M, Gisselsson D, Soller M, Hansen GB, Elfving P, Mitelman F. Dissecting karyotypic patterns in malignant melanomas: temporal clustering of losses and gains in melanoma karyotypic evolution. Int J Cancer 2004;108:57-65.
13. Balaban G, Herlyn M, Guerry D, 4th, et al. Cytogenetics of human malignant melanoma and premalignant lesions. Cancer Genet Cytogenet 1984;11:429-39.
14. Pathak S, Drwinga HL, Hsu TC. Involvement of chromosome 6in rearrangements in human malignant melanoma cell lines. Cytogenet Cell Genet 1983;36: 573-9.
15. Chen D, Gallie BL, Squire JA. Minimal regions of chromosomal imbalance in retinoblastoma detected by comparative genomic hybridization. Cancer Genet Cytogenet 2001;129:57-63.
16. Evans AJ, Gallie BL, Jewett MA, et al. Defining a 0.5-mb region of genomic gain on chromosome 6p22 in bladder cancer by quantitative-multiplex polymerase chain reaction. Am J Pathol 2004;164:285-93.
17. Grasemann C, Gratias S, Stephan H, et al. Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma. Oncogene 2005;24:6441-9.
18. Orlic M, Spencer CE, Wang L, Gallie BL. Expression analysis of 6p22 genomic gain in retinoblastoma. Genes Chromosomes Cancer 2006;45:72-82.
19. von Lindern M, van Baal S, Wiegant J, Raap A, Hagemeijer A, Grosveld G. Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3¶ half to different genes: characterization of the set gene. Mol Cell Biol 1992;12:3346-55.
20. Waldmann T, Scholten I, Kappes F, Hu HG, Knippers R. The DEK protein-an abundant and ubiquitous constituent of mammalian chromatin. Gene 2004;343:1-9.
21. Carro MS, Spiga FM, Quarto M, et al. DEK Expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle 2006;5:1202-7. 22. Wu Q, Li Z, Lin H, Han L, Liu S, Lin Z. DEK overexpression in uterine cervical cancers. Pathol Int 2008;58:378-82.
22. Sammons M, Wan SS, Vogel NL, Mientjes EJ, Grosveld G, Ashburner BP. Negative regulation of the RelA/p65 transactivation function by the product of the DEK proto-oncogene. J Biol Chem 2006;281:26802-12.
23. Faulkner NE, Hilfinger JM, Markovitz DM. Protein phosphatase 2A activates the HIV-2 promoter through enhancer elements that include the pets site. J Biol Chem 2001;276:25804-12.
24. Gamble MJ, Fisher RP. SET and PARP1 remove DEK from chromatin to permit access by the transcription machinery. Nat Struct Mol Biol 2007;14:548-55.
25. Kappes F, Scholten I, Richter N, Gruss C, Waldmann T. Functional domains of the ubiquitous chromatin protein DEK. Mol Cell Biol 2004;24:6000-10.
26. Mor-Vaknin N, Punturieri A, Sitwala K, et al. The DEK nuclear autoantigen is a secreted chemotactic factor. Mol Cell Biol 2006;26:9484-96.
27. Wise-Draper TM, Morreale RJ, Morris TA, et al. DEK proto-oncogene expression interferes with the normal epithelial differentiation program. Am J Pathol 2009;174: 71-81.
28. Wise-Draper TM, Allen HV, Thobe MN, et al. The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7. J Virol 2005;79:14309-17.
29. Kim DW, Chae JI, Kim JY, et al. Proteomic analysis of apoptosis related proteins regulated by proto-oncogene protein DEK. J Cell Biochem 2009.
30. Sitwala KV, Mor-Vaknin N, Markovitz DM. Minireview: DEK and gene regulation, oncogenesis and AIDS. Anticancer Res 2003;23:2155-8.
31. Wise-Draper TM, Allen HV, Jones EE, Habash KB, Matsuo H, Wells SI. Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions. Mol Cell Biol 2006;26:7506-19.
32. Devany M, Kappes F, Chen KM, Markovitz DM,Matsuo H. Solution NMR structure of the N-terminal domain of the human DEK protein. Protein Sci 2008;17:205-15.
33. Cleary J, Sitwala KV, Khodadoust MS, et al. p300/CBP-associated factor drives DEK into interchromatin granule clusters. J Biol Chem 2005;280:31760-7.
34. Grottke C, Mantwill K, Dietel M, Schadendorf D, Lage H. Identification of differentially expressed genes in human melanoma cells with acquired resistance to various antineoplastic drugs. Int J Cancer 2000;88: 535-46.
35. Kappes F, Damoc C, Knippers R, Przybylski M, Pinna LA, Gruss C. Phosphorylation by protein kinase CK2 changes the DNA binding properties of the human chromatin protein DEK. Mol Cell Biol 2004;24: 6011-20.
36. Denoyelle C, Abou-Rjaily G, Bezrookove V, et al. Antioncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol 2006;8:1053-63.
37. Wang G, Nikolovska-Coleska Z, Yang CY, et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem 2006; 49:6139-42.
38. Fernandez Y, Verhaegen M, Miller TP, et al. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res 2005;65:6294-304.
39. Croxton R, Ma Y, Song L, Haura EB, Cress WD. Direct repression of the Mcl-1 promoter by E2F1. Oncogene 2002;21:1359-69.
40. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell 2007;130:223-33.
41. Kappes F, Fahrer J, Khodadoust MS, et al. DEK is a poly(ADP-ribose)- acceptor in apoptosis and mediates resistance to genotoxic stress. Mol Cell Biol 2008;28: 3245-57.
42. Han J, Goldstein LA, Gastman BR, Froelich CJ, Yin XM, Rabinowich H. Degradation of Mcl-1 by granzyme B: implications for Bim-mediated mitochondrial apoptotic events. J Biol Chem 2004;279:22020-9.
43. Wolter KG, Verhaegen M, Fernandez Y, et al. Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins. Cell Death Differ 2007;14:1605-16.
44. Prieur A, Peeper DS. Cellular senescence in vivo: a barrier to tumorigenesis. CurrOpin Cell Biol 2008;20:150-5.
45. Zhuang D, Mannava S, Grachtchouk V, et al. C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells. Oncogene 2008;27:6623-34.
46. Ko SI, Lee IS, Kim JY, et al. Regulation of histone acetyltransferase activity of p300 and PCAF by protooncogene protein DEK. FEBS Lett 2006;580:3217-22.
47. Pietrzak M, Puzianowska-Kuznicka M. p53-dependent repression of the human MCL-1 gene encoding an anti-apoptotic member of the BCL-2 family: the role of Sp1 and of basic transcription factor binding sites in the MCL-1 promoter. Biol Chem 2008; 389:383-93.
48. Qin JZ, Xin H, Sitailo LA, Denning MF, Nickoloff BJ. Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA. Cancer Res 2006;66: 9636-45.
49. Boisvert-Adamo K, Longmate W, Abel EV, Aplin AE. Mcl-1 is required for melanoma cell resistance to anoikis. Mol Cancer Res 2009;7:549-56.